Lv1
100 积分 2025-09-09 加入
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
12小时前
待确认
Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma
2天前
已完结
Global and regional cancer burden attributable to modifiable risk factors to inform prevention
6天前
已完结
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
8天前
已完结
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
14天前
已完结
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
14天前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
16天前
已完结
Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma
1个月前
已关闭
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
1个月前
已完结
Cures lightning from a torticollis with intradermal histamine
1个月前
已关闭
皖公网安备34019202002308
